Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nilutamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR known ✓ | P10275 | 15/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nilutamide SCHEMBL12670 | 1.00 | AR (1.00) | ARLMNASMN1; SMN2MEN1TP53 | |
| Nilutamide SCHEMBL29351021 | 1.00 | AR (1.00) | ARLMNASMN1; SMN2MEN1TP53 | |
| Nilutamide SCHEMBL28562851 | 0.99 | AR (0.98) | ARLMNASMN1; SMN2MEN1TP53 | |
| Nilutamide SCHEMBL20695037 | 0.94 | AR (0.89) | ARLMNASMN1; SMN2MEN1TP53 | |
| Nilutamide SCHEMBL5579273 | 0.94 | AR (0.89) | ARLMNASMN1; SMN2MEN1TP53 | |
| SCHEMBL10324758 | 0.90 | AR (0.81) | ARLMNASMN1; SMN2MEN1TP53 | |
| SCHEMBL8407306 | 0.88 | AR (0.78) | ARLMNASMN1; SMN2MEN1TP53 | |
| Nilutamide SCHEMBL5537957 | 0.88 | AR (0.77) | ARLMNASMN1; SMN2MEN1TP53 | |
| SCHEMBL629458 | 0.85 | AR (0.74) | ARLMNASMN1; SMN2MEN1TP53 | |
| Nilutamide SCHEMBL115340 | 0.85 | AR (0.73) | ARLMNASMN1; SMN2MEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10933061-B2 | Pyrvinium pamoate therapies and methods of use | SHEPHERD THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| US-20190209549-A1 | PYRVINIUM PAMOATE THERAPIES AND METHODS OF USE | SHEPHERD THERAPEUTICS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-20190175560-A1 | MEBENDAZOLE CANCER THERAPIES AND METHODS OF USE | SHEPHERD THERAPEUTICS, INC. | 2019-06-13 | — | — | US | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| WO-2014036520-A1 | COMBINATION THERAPIES COMPRISING ANTI-ERBB3 AGENTS | MERRIMACK PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | WO | disclosed |
| EP-2678359-A2 | COMBINATION THERAPIES COMPRISING ANTI-ERBB3 AGENTS | Merrimack Pharmaceuticals, Inc. (US) | 2014-01-01 | — | — | EP | disclosed |
| WO-2012116317-A2 | COMBINATION THERAPIES COMPRISING ANTI-ERBB3 AGENTS | MERRIMACK PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | WO | disclosed |
| EP-2475366-A1 | SUBSTITUTED (HETEROARYLMETHYL) THIOHYDANTOINS AS ANTICANCER DRUGS | Bayer Pharma Aktiengesellschaft (DE) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011029782-A1 | SUBSTITUTED (HETEROARYLMETHYL) THIOHYDANTOINS AS ANTICANCER DRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-17 | — | — | WO | disclosed |
| CN-1371286-A | Use of cyclooxygenase-2 inhibitor matrix metallappoteinase inhibitor antineoplastic agent and optionally radiation as combination treatment of neoplasia | SEARLE & CO (US) | 2002-09-25 | — | — | CN | disclosed |
| CN-1346282-A | Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as combination therapy method in treating neoplasia | SEARLE & CO (US) | 2002-04-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190175560-A1 | MEBENDAZOLE CANCER THERAPIES AND METHODS OF USE | CYP3A43, HNMT, TUBB3 | AR 1583/4885LMNA 3403/4885SMN1; SMN2 3812/4885 |
| US-10933061-B2 | Pyrvinium pamoate therapies and methods of use | TP53, MSH2, BRCA1 | AR 874/4885LMNA 3458/4885SMN1; SMN2 1262/4885 |
| US-20190209549-A1 | PYRVINIUM PAMOATE THERAPIES AND METHODS OF USE | TP53, MSH2, BRCA1 | AR 874/4885LMNA 3458/4885SMN1; SMN2 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.